Keyword: Idera Pharmaceuticals
Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.
BioCryst’s shareholders voted down a proposal to merge with Idera Pharmaceuticals and form a combined rare disease company.
Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.
The 44% overall response rate in patients treated with IMO-2125 and Yervoy has emboldened Idera to move into phase 3 early next year.